Purpose: To study the clinical effect of combining insulin aspart with different drugs in the treatment oftype 2 diabetes mellitus (T2DM).Methods: Two hundred and thirty-seven T2DM patients admitted to the Endocrinology Department of the Second Affiliated Hospital of Kunming Medical University from March to September 2018 were selected as subjects in this study. Miglitol and metformin were used in combination with insulin aspart in the treatment of T2DM. In addition, data on the effectiveness and safety of different treatment options,such as patient’s weight, waist circumference, blood glucose indicators, indices of heart, liver and kidney functions, and incidence of complications were recorded and compared between the two groups.Results: The use of a combination of miglitol and insulin aspart produced an excellent hypoglycaemic effect, and it significantly reduced the incidence of sensory neuropathy in the eyes and distal limbs (p < 0.05). The use of combination of metformin and insulin aspart effectively protected the heart and kidney, and prevented hypoglycaemia (p < 0.05).Conclusion: These results suggest that treatment with a combination of miglitol and insulin aspart is suitable for patients with T2DM whose blood sugar levels are out of control, while combined treatment with metformin and insulin aspart is more suited for patients who desire to reduce blood sugar and blood lipids through weight loss, and patients with cardiac and renal insufficiency.
The present work selected 120 patients, affected by diabetes, as control subjects in the Affiliated Hospital of Kunming Medical University. According to the principle of random distribution, two groups were established, miglitol study group (65 cases) and metformin control group (55 cases). The Ag + disinfectant sampling needle is a rapid detection tool to evaluate the efficacy of diabetes in both groups. The related biochemical indexes of the patients were measured before and after treatment at the 3rd, 6th, and 12th weeks. The test results showed that there were significant differences in fasting blood glucose value (FBG) and postprandial blood glucose value (2hFBG) among the two groups after 3-, 6-, and 12-month treatment. With the extension of treatment, the blood glucose level of diabetic patients gradually stabilized. Fasting insulin level (FINS) and postprandial two-hour insulin level (2hINS) increased gradually. At the 12th week, by measuring the HbA1c level of the patients, it was found decreasing significantly. In detail, the study group decreased more significantly than the control group, and the incidence of adverse reactions during treatment was 10.8% and 23.6%, respectively, with a significant statistical significance (P < 0 05). Meanwhile, we measured other biochemical indexes of patients from both groups after drug treatment. At the 6th week, the levels of glycosylated glycoprotein (HbA1c), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in the study group decreased more than in the control group. Therefore, miglitol shows a better hypoglycemic effect on type 2 diabetes, and the gastrointestinal adverse reactions are lesser than metformin, which is more worthy in clinical application.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.